ALTASCIENCES
Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City.
James joins Altasciences having previously worked as Vice President of Research at Akron Children’s Hospital, and most recently as Vice President of Research Operations for Circuit Clinical.
“James’ proven leadership skills, and deep knowledge of all phases of clinical research, will be invaluable in delivering expert guidance for our clients along their early-phase clinical journey,” said Ingrid Holmes, Vice President, Clinical Operations, Altasciences.
With close to a decade of experience in the healthcare and pharmaceutical sectors, including clinical pharmacology, James will apply his knowledge to oversee the day-to-day management of clinical operations at Altasciences’ 140-bed, Phase I, clinical pharmacology unit in Kansas City.
“It is rewarding to be joining a team that has been in place for almost three decades, a team committed to quality, excellence, integrity, and respect—focused on helping to bring better therapies to the patients who need them, faster,” says James.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240129556297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTIMindtree Launches ‘BlueVerse’ — An AI Ecosystem that will Define the Enterprise of the Future19.6.2025 11:30:00 CEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the launch of a new business unit and suite of AI services and solutions: BlueVerse. Designed as a complete AI ecosystem, it helps enterprises accelerate their AI concept-to-value journey. This ecosystem is a universe of components that enterprises need to elevate business operations, achieve breakthrough productivity, and create transformational customer experiences. BlueVerse Marketplace currently has over 300 industry and function-specific agents and ensures seamless interoperability and a growing connector ecosystem. It is underpinned by responsible AI governance, delivering enterprise-grade trust and scalability. BlueVerse Productized Services utilize repeatable frameworks, accelerators, and industry-specific solution kits. At launch, BlueVerse will offer pre-built solutions for Marketing Services and Contact Center as a Service (CCaaS). With Marketing Services busines
KIKO Milano Partners with Logistics Reply to Accelerate E-Commerce Delivery in the UK Market19.6.2025 10:00:00 CEST | Press release
Logistics Reply, the Reply group company specialising in innovative supply chain solutions has partnered with KIKO Milano, the global cosmetics brand renowned for its cutting edge, high-quality beauty products, to transform its e-commerce operations in the UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619841029/en/ This partnership represents a strategic milestone in KIKO’s broader digital transformation journey and reinforces its commitment to operational excellence and an exceptional customer experience. With rapid growth in the UK market and a rising demand for online shopping and fast home delivery, KIKO recognized the need to evolve its supply chain operations. To meet these challenges, KIKO opened a new dark store in London and selected Logistics Reply with its LEA Reply™ Warehouse Management System (WMS) to build a more scalable and agile logistics infrastructure. A dark store is a retail distribution centre t
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases19.6.2025 09:35:00 CEST | Press release
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative solutions for people living with rare diseases, today announced the recipients of its "Find For Rare" research grant program. The independently assessed, expert-led research grant initiative aims to improve patient care and management by recognising innovative research in three lysosomal diseases: Fabry disease, alpha-mannosidosis, and cystinosis. The selected projects demonstrated significant potential to address unmet needs within these rare communities. The recipients include: Fabry disease: Mitra Tavakoli, University of Exeter, Exeter, UK, for her project "FAB-PAIN: Precise phenotyping of neuropathy using a range of novel biomarkers in Fabry Disease” Project overview: This project aims to explore a range of novel biomarkers to better understand the pain pathways and its pathophysiology in Fabry disease. The findings may lead to the development of a range of new neuropathic biomarkers,
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy19.6.2025 09:15:00 CEST | Press release
Presented at EACR 2025, promising results show the impact of Brenus Pharma and InSphero’s collaboration in advancing translational immunotherapy through scalable 3D tumor models. Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer. Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorectal cancer spheroids using tumor cell lines co-cultured with fibroblasts. The vitrification method preserves morphology, stromal integrity, and viability after thawing, enabling realistic evaluation of STC-1010’s therapeutic potential under conditions mimicking in vivo human tumors. Previous studies showed that STC-1010 antigens were effectively processed
Textron Aviation Defense and Thai Aviation Industries Sign Agreement to Support Royal Thai Air Force19.6.2025 08:30:00 CEST | Press release
During the Paris Air Show, Textron Aviation Defense LLC., a Textron Inc. (NYSE: TXT) company, and Thai Aviation Industries Co., Ltd. signed a Memorandum of Agreement to work together on a sustainment program for the Royal Thai Air Force (RTAF). This program will support RTAF's fleets of Beechcraft T-6TH and AT-6TH aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618711147/en/ Textron Aviation Defense LLC. and Thai Aviation Industries Co., Ltd. sign a Memorandum of Agreement to sustain Beechcraft T-6TH trainer and AT-6TH light attack aircraft for the Royal Thai Air Force (RTAF) The Beechcraft T-6TH trainer and AT-6TH light attack aircraft are designed and manufactured by Textron Aviation Defense LLC., a wholly owned subsidiary of Textron Aviation Inc. Textron Aviation Defense, based in Wichita, Kansas, USA, is the original equipment manufacturer (OEM) for these aircraft. Thai Aviation Industries, located in Bangkok
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom